High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma

Elevated B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serum levels have been reported to correlate with worse prognosis in B cell-derived malignancies. However, limited information exists regarding the prognostic significance of BAFF and APRIL serum levels in follicula...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2015-01, Vol.94 (1), p.79-88
Hauptverfasser:	Li, Ya-Jun, Li, Zhi-Ming, Xia, Zhong-Jun, Li, Su, Xia, Yi, Huang, Hui-Qiang, Huang, Jia-Jia, Yi, Ping-Yong, Jiang, Wen-Qi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged B-Cell Activating Factor - blood Biomarkers - blood Female Follow-Up Studies Hematology Humans Lymphoma, Follicular - blood Lymphoma, Follicular - diagnosis Lymphoma, Follicular - mortality Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Survival Rate - trends Treatment Outcome Tumor Necrosis Factor Ligand Superfamily Member 13 - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Elevated B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serum levels have been reported to correlate with worse prognosis in B cell-derived malignancies. However, limited information exists regarding the prognostic significance of BAFF and APRIL serum levels in follicular lymphoma (FL). We measured BAFF and APRIL serum levels for 81 patients with newly diagnosed FL and 12 healthy controls. The mean ± standard deviation (SD) BAFF serum level (1,193.86 ± 1,126.51 pg/ml) was higher in patients with FL than that in the controls (477.16 ± 155.55 pg/ml; P
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-014-2173-2